2D 3D
	ID	DDInter1517
	Drug Type	small molecule
	Molecular Formula	C14H12F3N3O5
	Molecular Weight	359.257
	CAS Number	187235-37-6
	Description	Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy regimens.[A182915] Pretomanid is an antimycobacterial agent that is administered with [Bedaquiline] and [Linezolid] to treat resistant forms of pulmonary TB. It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019.[L8048,L8066] Unlike other therapeutic regimens for the treatment of resistant TB, which may take 18 months or longer and may not be effective, the pretomanid-containing regimen allows for a more efficacious and shorter duration of treatment with fewer drugs.[L8066]
	ATC Classification	J04AK08
IUPAC Name	(6S)-2-nitro-6-{[4-(trifluoromethoxy)phenyl]methoxy}-5H,6H,7H-imidazo[2,1-b][1,3]oxazine
InChI	ZLHZLMOSPGACSZ-NSHDSACASA-N
Canonical SMILES	[O-][N+](=O)C1=CN2C[C@@H](COC2=N1)OCC1=CC=C(OC(F)(F)F)C=C1
Useful Links	DrugBank PubChem Substance ChemSpider BindingDB Wikipedia ChEMBL ZINC